Topempfehlung UROCOR (UCOR) gibt den Startschuß!!! - 500 Beiträge pro Seite
eröffnet am 09.03.00 20:54:06 von
neuester Beitrag 22.01.01 23:45:24 von
neuester Beitrag 22.01.01 23:45:24 von
Beiträge: 5
ID: 90.850
ID: 90.850
Aufrufe heute: 0
Gesamt: 410
Gesamt: 410
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 08.05.24, 11:56 | 429 | |
| gestern 20:31 | 149 | |
| gestern 18:51 | 140 | |
| gestern 22:50 | 124 | |
| gestern 22:33 | 121 | |
| 11.05.24, 11:52 | 111 | |
| 17.08.12, 13:14 | 99 | |
| vor 54 Minuten | 94 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 0,2170 | +3,33 | 48 | |||
| 2. | 2. | 18.763,00 | -0,01 | 44 | |||
| 3. | 3. | 168,47 | -2,04 | 28 | |||
| 4. | 4. | 0,1640 | 0,00 | 22 | |||
| 5. | 6. | 0,2980 | -3,87 | 17 | |||
| 6. | 5. | 2,5600 | -6,91 | 16 | |||
| 7. | 7. | 898,78 | +1,27 | 13 | |||
| 8. | 8. | 10,320 | 0,00 | 12 |
Feedback
Hallo zusammen
So langsam aber sicher kommt Bewegung in den Aktienkurs von Urocor (WK: 900847)!!!
Zur Zeit werden Aktienpakete umplaziert, dann kommt eine Kaufempfehlung und weg ist der Kurs. Dies hat man in den letzten Wochen bei Knorr und VMR gesehen. Urocor hat meiner Ansicht nach das Potential sich in zwei bis drei Jahren zu verzehnfachen - also ein echter Tenbagger.
Leider ist in D noch kein großer Handel, doch was nicht ist, kann ja noch werden!
DocBio
So langsam aber sicher kommt Bewegung in den Aktienkurs von Urocor (WK: 900847)!!!
Zur Zeit werden Aktienpakete umplaziert, dann kommt eine Kaufempfehlung und weg ist der Kurs. Dies hat man in den letzten Wochen bei Knorr und VMR gesehen. Urocor hat meiner Ansicht nach das Potential sich in zwei bis drei Jahren zu verzehnfachen - also ein echter Tenbagger.
Leider ist in D noch kein großer Handel, doch was nicht ist, kann ja noch werden!
DocBio
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Hi Matzeli
Da hab ich doch was für dich gefunden!!!
UCOR
7 5/16
+1 13/16
Thursday March 9, 3:25 pm Eastern Time
Company Press Release
SOURCE: UroCor, Inc.
FDA Clears PACIS(TM) BCG for Bladder Cancer: Immunotherapy Drug Licensed for Marketing in the U.S. by UroCor And Manufactured by BioChem Pharma
PACIS is UroCor`s Latest Therapeutic to Leverage the Company`s Diagnostic Sales Relationship with Office-Based Urologists Nationally
OKLAHOMA CITY, March 9 /PRNewswire/ -- UroCor, Inc., (Nasdaq: UCOR - news), said today that BioChem Pharma`s PACIS(TM) BCG intravesical immunotherapy, which UroCor has exclusively licensed for marketing in the U.S., has received FDA clearance as a treatment for carcinoma-in-situ of the urinary bladder. UroCor`s marketing launch for PACIS is estimated for mid 2000.
PACIS® contains live, attenuated mycobacteria. Because of the potential risk of transmission, it should be prepared, handled and disposed of as a biohazardous material.
Already approved for use in several other countries, including Canada, the drug features the original Bacillus Calmette-Guerin (BCG), substrain Montreal, for treating carcinoma-in-situ of the urinary bladder. The recommended course of treatment is a single dose, once per week, for six weeks, usually administered in the physician`s office.
``We are excited about the upcoming launch of PACIS for two reasons,`` noted Michael W. George, President and CEO of UroCor. ``First, this therapeutic will provide another therapy for urologists who treat patients with carcinoma-in-situ of the urinary bladder. Second, the marketing of PACIS advances UroCor`s strategy to become a leading urological therapeutics company by leveraging our core skills and market channel in diagnostics, where we have established relationships with office-based urologists.``
The Armand Frappier strain of BCG has more than 25 years of clinical experience worldwide.
According to the American Cancer Society, bladder cancer is the sixth most common cancer in the U.S., and the organization estimates there will be about 53,2000 new cases reported this year and about 12,200 people will die of bladder cancer this year.
``Even though PACIS is not the first BCG therapeutic on the market,`` George said, ``it is the only one with the original strain. From a competitive standpoint, UroCor is the only U.S. marketer of BCG with a sales force that markets diagnostics and therapeutics to urologists.`` In clinical studies of 292 patients, PACIS was well-tolerated, with the most common and serious adverse reactions being dysuria/cystitis (9%), increased urgency and frequency of urination (7%), and hematuria (6%).
BioChem Pharma Inc., headquartered in Laval, Quebec, Canada, is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of human disease, with a focus in the anti-infective and anticancer areas. Under the agreement with BioChem Pharma Inc., and as a result of the FDA approvals, UroCor is obligated to make its final milestone payment to BioChem Pharma in the amount of $1.75 million.
UroCor markets a comprehensive range of integrated products and services to assist in detecting, diagnosing, treating and managing prostate cancer, bladder cancer, kidney stones and other complex urologic disorders directly to urologists and managed care organizations. The Company`s primary focus is helping urologists improve patient care and outcomes while reducing the total cost of managing these diseases. The Company presently serves many of the office-based urologists in the United States, many of them over its Internet-based wide area network.
Safe Harbor Statement
Statements in this news release that are not strictly historical, including statements as to plans, objectives and future financial performance, are ``forward-looking`` statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Although UroCor believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that the expectations will prove to be correct. Factors that could cause actual results to differ materially from UroCor`s expectations include, among others, competition within the healthcare and medical services industries; the effects of government regulation and reimbursement policies on the healthcare market and the Company, including the possibility of being deemed not to be in compliance with federal or state regulatory requirements; the Company`s access to and the market`s acceptance of new diagnostic and therapeutic products; the Company`s ability to market and distribute diagnostic and therapeutic products profitably; the Company`s ability to maintain or expand contractual relationships with managed care organizations; the Company`s ability to acquire or develop and implement appropriate management information systems; as well as the risks, uncertainties and other factors described from time to time in the Company`s periodic filings with the Securities and Exchange Commission.
For more information about UroCor, including prescribing information for PACIS, toll-free via fax, dial 1-800-PRO-INFO or 1-800-776-4636, follow the voice menu prompts and enter the company code UCOR or 8267 on any touch tone phone, or visit the UroCor page on the FRB website at www.frbinc.com .
Visit the UroCor website at www.urocor.com .
SOURCE: UroCor, Inc.
Urocor ist ein absolut langfristiges Investment!
Grüße, DocBio
Da hab ich doch was für dich gefunden!!!
UCOR
7 5/16
+1 13/16
Thursday March 9, 3:25 pm Eastern Time
Company Press Release
SOURCE: UroCor, Inc.
FDA Clears PACIS(TM) BCG for Bladder Cancer: Immunotherapy Drug Licensed for Marketing in the U.S. by UroCor And Manufactured by BioChem Pharma
PACIS is UroCor`s Latest Therapeutic to Leverage the Company`s Diagnostic Sales Relationship with Office-Based Urologists Nationally
OKLAHOMA CITY, March 9 /PRNewswire/ -- UroCor, Inc., (Nasdaq: UCOR - news), said today that BioChem Pharma`s PACIS(TM) BCG intravesical immunotherapy, which UroCor has exclusively licensed for marketing in the U.S., has received FDA clearance as a treatment for carcinoma-in-situ of the urinary bladder. UroCor`s marketing launch for PACIS is estimated for mid 2000.
PACIS® contains live, attenuated mycobacteria. Because of the potential risk of transmission, it should be prepared, handled and disposed of as a biohazardous material.
Already approved for use in several other countries, including Canada, the drug features the original Bacillus Calmette-Guerin (BCG), substrain Montreal, for treating carcinoma-in-situ of the urinary bladder. The recommended course of treatment is a single dose, once per week, for six weeks, usually administered in the physician`s office.
``We are excited about the upcoming launch of PACIS for two reasons,`` noted Michael W. George, President and CEO of UroCor. ``First, this therapeutic will provide another therapy for urologists who treat patients with carcinoma-in-situ of the urinary bladder. Second, the marketing of PACIS advances UroCor`s strategy to become a leading urological therapeutics company by leveraging our core skills and market channel in diagnostics, where we have established relationships with office-based urologists.``
The Armand Frappier strain of BCG has more than 25 years of clinical experience worldwide.
According to the American Cancer Society, bladder cancer is the sixth most common cancer in the U.S., and the organization estimates there will be about 53,2000 new cases reported this year and about 12,200 people will die of bladder cancer this year.
``Even though PACIS is not the first BCG therapeutic on the market,`` George said, ``it is the only one with the original strain. From a competitive standpoint, UroCor is the only U.S. marketer of BCG with a sales force that markets diagnostics and therapeutics to urologists.`` In clinical studies of 292 patients, PACIS was well-tolerated, with the most common and serious adverse reactions being dysuria/cystitis (9%), increased urgency and frequency of urination (7%), and hematuria (6%).
BioChem Pharma Inc., headquartered in Laval, Quebec, Canada, is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of human disease, with a focus in the anti-infective and anticancer areas. Under the agreement with BioChem Pharma Inc., and as a result of the FDA approvals, UroCor is obligated to make its final milestone payment to BioChem Pharma in the amount of $1.75 million.
UroCor markets a comprehensive range of integrated products and services to assist in detecting, diagnosing, treating and managing prostate cancer, bladder cancer, kidney stones and other complex urologic disorders directly to urologists and managed care organizations. The Company`s primary focus is helping urologists improve patient care and outcomes while reducing the total cost of managing these diseases. The Company presently serves many of the office-based urologists in the United States, many of them over its Internet-based wide area network.
Safe Harbor Statement
Statements in this news release that are not strictly historical, including statements as to plans, objectives and future financial performance, are ``forward-looking`` statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Although UroCor believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that the expectations will prove to be correct. Factors that could cause actual results to differ materially from UroCor`s expectations include, among others, competition within the healthcare and medical services industries; the effects of government regulation and reimbursement policies on the healthcare market and the Company, including the possibility of being deemed not to be in compliance with federal or state regulatory requirements; the Company`s access to and the market`s acceptance of new diagnostic and therapeutic products; the Company`s ability to market and distribute diagnostic and therapeutic products profitably; the Company`s ability to maintain or expand contractual relationships with managed care organizations; the Company`s ability to acquire or develop and implement appropriate management information systems; as well as the risks, uncertainties and other factors described from time to time in the Company`s periodic filings with the Securities and Exchange Commission.
For more information about UroCor, including prescribing information for PACIS, toll-free via fax, dial 1-800-PRO-INFO or 1-800-776-4636, follow the voice menu prompts and enter the company code UCOR or 8267 on any touch tone phone, or visit the UroCor page on the FRB website at www.frbinc.com .
Visit the UroCor website at www.urocor.com .
SOURCE: UroCor, Inc.
Urocor ist ein absolut langfristiges Investment!
Grüße, DocBio
Wer kann nähere Angaben über diese Aktie machen. In den letzten Wochen ist sie kontinuierlich gestiegen.
Sollte man sich diesen Wert ins Depot legen?
Sollte man sich diesen Wert ins Depot legen?
Hi
Wer hat investiert???
Man hat ne Menge Geld mit diesem Wert verdienen können!
Mir scheint, dass der nächste Move nach oben kommt - Kursziel vorerst 15 $, wenn der Widerstand bei 9$ nachhaltig überwunden wird.
DocBio
Wer hat investiert???
Man hat ne Menge Geld mit diesem Wert verdienen können!
Mir scheint, dass der nächste Move nach oben kommt - Kursziel vorerst 15 $, wenn der Widerstand bei 9$ nachhaltig überwunden wird.
DocBio
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 48 | ||
| 44 | ||
| 27 | ||
| 22 | ||
| 17 | ||
| 17 | ||
| 13 | ||
| 12 | ||
| 10 | ||
| 10 |
| Wertpapier | Beiträge | |
|---|---|---|
| 10 | ||
| 8 | ||
| 7 | ||
| 7 | ||
| 7 | ||
| 7 | ||
| 6 | ||
| 6 | ||
| 5 | ||
| 5 |
